Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified May 2025 by University of Utah
Sponsor
University of Utah
Information Provided by (Responsible Party)
Whitnee Hogan, MD (Assistant Professor)
Clinicaltrials.gov Identifier
NCT05767385
Other Study ID Numbers:
IRB_00145850
First Submitted
February 28, 2023
First Posted
March 13, 2023
Last Update Posted
June 24, 2025
Last Verified
May 2025

ClinicalTrials.gov processed this data on June 2025Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Aim 1:

Determine the association of baseline cerebrovascular resistance and reactivity and pre-operative neurobehavior in neonates with complex congenital heart disease (CCHD).

Exposures: The baseline middle cerebral artery pulsatility index (MCA-PI) and change in MCA-PI.

Analyses: Our principal analyses for Aim 1 will use separate linear regression models to relate the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) attention score to 1) the baseline MCA-PI while controlling for maternal age, infant sex, race/ethnicity, and SDOH measures (maternal education, socioeconomic status (SES), insurance status), and clinical site, and 2) the change in MCA-PI adjusted for baseline MCA-PI while controlling for the same set of covariates. If the NNNS attention score distribution is skewed, we will consider transformations so that model residual plots achieve approximate normality. The covariates in the above regression analyses exclude factors that may potentially lie on the causal pathway from the MCA-PI to the attention score to avoid risk of over adjustment. In secondary analyses, 2 regression analyses will be repeated after additional adjustment for the maternal-fetal environment indicator(s), CCHD category, and age at NNNS evaluation. As a secondary analysis, we will evaluate the interaction between baseline MCA-PI and change in MCA-PI. For this analysis, we will consider dichotomizing baseline MCA-PI to facilitate interpretation of the interaction effect.

Aim 2:

Determine the impact of patient and environmental factors on cerebrovascular resistance and reactivity Exposures: Patient factors including CCHD category, indicators of the maternal-fetal environment, and SDOH

Analysis: The primary analysis for Aim 2 will investigate the joint relationship of the MCA-PI with SDOH measures and the maternal-fetal comorbidity indicator while accounting for the CCHD category (defined as Left sided obstructive lesion, Right sided obstructive lesion, Dextro-Transposition of the Great Arteries, and Other). We will apply multiple linear regression to relate the MCA-PI to the SDOH measures and a maternal-fetal comorbidity indicator for the presence of any of maternal hypertension, diabetes, pre-eclampsia, eclampsia, and abruption, prematurity, and small for gestational age. The CCHD category will also be a covariate in the regression model. Additional exploratory regression analyses will include pairwise interaction terms between the maternal-fetal comorbidity indicator(s) with the SDOH measures to assess if the association of the maternal-fetal environment indicator(s) with the MCA-PI varies across the different levels of the SDOH measures. We will perform a separate multiple regression with the change in the MCA-PI as the outcome and with the baseline MCA-PI as an additional covariate.

Condition or DiseaseIntervention/Treatment
Congenital Heart Disease in ChildrenHypoxiaNeurodevelopmental DisordersComplex Congenital Heart Disease
Procedure: Single Arm

Study Design

Study TypeInterventional
Actual Enrollment150 participants
Design AllocationN/A
Interventional ModelSingle Group Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleFetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
Study Start DateDecember 16, 2021
Actual Primary Completion DateNovember 30, 2025
Actual Study Completion DateNovember 30, 2025

Groups and Cohorts

Group/CohortIntervention/Treatment
Single Arm
Maternal Hyperoxia (MH) will be administered to pregnant patients after their standard of care fetal echocardiogram has been performed at their scheduled fetal cardiology visit at ³28 weeks gestation. The evaluation at ³28 weeks was chosen since gestational age impacts both the cardiovascular and cerebrovascular response to MH.31 The evaluation will extend the duration of the visit by approximately 30 minutes but additional evaluations or visits for the study will not be required.
Procedure: Single Arm
* Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care. * Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete. * Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline.

Outcome Measures

Primary Outcome Measures
  1. Pre-operative Neonatal Network Neurobehavioral Scale (NNNS) attention scores
    The NeoNatal Neurobehavioral Scale (NNNS-II) examines the neurobehavioral organization, neurological reflexes, motor development - active and passive tone, and signs of stress and withdrawal of the at-risk and drug-exposed infant
  2. Baseline MCA-PI and change in MCA-PI with Maternal Hyperoxia
    The fetal middle cerebral artery (MCA) pulsatility index (PI)

Eligibility Criteria

Ages Eligible for Study(Child, Adult)
Sexes Eligible for StudyFemale
Accepts Healthy VolunteersNo
Inclusion Criteria
Pregnant women 18 years of age and over with a singleton fetus with known or suspected congenital heart disease anticipated to need intervention or surgery within 30 days of birth.
Exclusion Criteria
Known fetal chromosomal or genetic abnormalities
Multiple gestation pregnancy
Fetal extra-cardiac anomalies

Contacts and Locations

Sponsors and CollaboratorsUniversity of Utah
Locations
University of California San Francisco | San Francisco California, United States, 94143Children's National Medical Center | Washington D.C. District of Columbia, United States, 20010Maine Medical Center | Scarborough Maine, United States, 04074Primary Children's Hospital | Salt Lake City Utah, United States, 84113University of Utah | Salt Lake City Utah, United States, 84132